Moomoo AI 已提取核心信息
On December 31, 2023, HOOKIPA Pharma Inc. was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission (SEC), indicating a change in ownership by certain investment entities. The filing was made by EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P., collectively referred to as the 'Filers.' According to the filing, EcoR1 Capital, LLC and Oleg Nodelman reported shared voting and dispositive power over 4,595,024 shares of HOOKIPA Pharma's common stock, representing 4.8% of the company's class. Similarly, EcoR1 Capital Fund Qualified, L.P. reported shared voting and dispositive power over 4,252,204 shares, representing 4.4% of the class. The Filers have disclaimed beneficial ownership of the stock except to the extent of their pecuniary interest. The filing also indicated that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of HOOKIPA Pharma. The percentages reported are based on 96,550,590 shares of Common Stock outstanding as of December 20, 2023. The principal business office of the Filers is located in San Francisco, California.
On December 31, 2023, HOOKIPA Pharma Inc. was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission (SEC), indicating a change in ownership by certain investment entities. The filing was made by EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P., collectively referred to as the 'Filers.' According to the filing, EcoR1 Capital, LLC and Oleg Nodelman reported shared voting and dispositive power over 4,595,024 shares of HOOKIPA Pharma's common stock, representing 4.8% of the company's class. Similarly, EcoR1 Capital Fund Qualified, L.P. reported shared voting and dispositive power over 4,252,204 shares, representing 4.4% of the class. The Filers have disclaimed beneficial ownership of the stock except to the extent of their pecuniary interest. The filing also indicated that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of HOOKIPA Pharma. The percentages reported are based on 96,550,590 shares of Common Stock outstanding as of December 20, 2023. The principal business office of the Filers is located in San Francisco, California.
2023年12月31日，HOOKIPA Pharma Inc.成为向美国证券交易委员会（SEC）提交的附表13G文件的主体，该文件表明某些投资实体的所有权发生了变化。该文件由EcoR1 Capital, LLC、Oleg Nodelman和EcoR1 Capital Fund Qualified, L.P.（统称为 “申报人”）提交。文件显示，EcoR1 Capital, LLC和奥列格·诺德尔曼报告了对HOOKIPA Pharma普通股的4595,024股的共同投票权和处置权，占该公司同类股的4.8％。同样，EcoR1资本基金合格有限责任公司报告了对4,252,204股股票的共享投票权和处置...展开全部
2023年12月31日，HOOKIPA Pharma Inc.成为向美国证券交易委员会（SEC）提交的附表13G文件的主体，该文件表明某些投资实体的所有权发生了变化。该文件由EcoR1 Capital, LLC、Oleg Nodelman和EcoR1 Capital Fund Qualified, L.P.（统称为 “申报人”）提交。文件显示，EcoR1 Capital, LLC和奥列格·诺德尔曼报告了对HOOKIPA Pharma普通股的4595,024股的共同投票权和处置权，占该公司同类股的4.8％。同样，EcoR1资本基金合格有限责任公司报告了对4,252,204股股票的共享投票权和处置权，占该类别的4.4％。申报人已放弃对股票的实益所有权，但金钱利益除外。该文件还显示，这些证券是在正常业务过程中收购的，不是为了改变或影响HOOKIPA Pharma的控制权。报告的百分比基于截至2023年12月20日的96,550,590股已发行普通股。申报人的主要业务办公室位于加利福尼亚州的旧金山。
有用
没用